Gene variation affects patients' response to Plavix

10/26/2010 | Yahoo!

U.S. researchers analyzed nine published studies and found that patients with a variation of the CYP2C19 gene who underwent heart surgery were less likely to benefit from Plavix, an anti-clotting drug from Bristol-Meyers Squibb and Sanofi-Aventis. They said a genetic test might help pinpoint patients who are most likely to respond to the treatment.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC